• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Champion Real Estate Investment Trust
Ecolomondo Corp
Euro Sun Mining Inc
First Hydrogen Corp
Landstar System, Inc. - Common Stock
Rhinebeck Bancorp, Inc. - Common Stock
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Small Pharma Inc (OP:DMTTF)

N/A UNCHANGED
Last Price Updated: 3:59 PM EDT, Oct 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Small Pharma Inc

< Previous 1 2 Next >
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Strategic Acquisition, Poised as Leader in Psychedelics Sector
October 23, 2023
Via Investor Brand Network
Topics Intellectual Property
News headline image
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
October 23, 2023
From Cybin Inc.
Via Business Wire
News headline image
Small Pharma Reports Fiscal Second Quarter 2024 Highlights
October 19, 2023
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Obtains Final Order Approving Arrangement
October 17, 2023
From Cybin Inc.
Via Business Wire
News headline image
Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders
October 12, 2023
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
September 26, 2023
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Cybin to Acquire Small Pharma Inc.
August 28, 2023
- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for... 
Via Newsfile
Topics Intellectual Property
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Acquisition That Will Create ‘Clear Market Leader in Novel Psychedelic Therapeutics’
August 28, 2023
Via Investor Brand Network
Topics Intellectual Property
News headline image
Cybin to Acquire Small Pharma Inc.
August 28, 2023
From Cybin Inc.
Via Business Wire
News headline image
Small Pharma Reports Fiscal First Quarter 2024 Highlights
July 27, 2023
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Announces SPL028 R&D Strategy Update
July 05, 2023
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Announces Management Team Change
July 05, 2023
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights
June 28, 2023
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Announces Significant Developments In Intellectual Property Portfolio
May 25, 2023
5 new patent grants, 3 expected upcoming patent grants, and 8 notices of allowance in key international jurisdictions 
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology
May 03, 2023
Chief Medical and Scientific Officer, Dr. Carol Routledge, will deliver a poster presentation on data from the Company’s SPL026 Phase IIa clinical trial in patients with Major Depressive Disorder 
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026
April 04, 2023
Approximately two-thirds of trial patients with Major Depressive Disorder achieving remission following SPL026 treatment sustained remission to six-months 
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry
March 07, 2023
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results
March 07, 2023
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference
March 01, 2023
Company will also host a cocktail reception on Tuesday, March 7 
From Small Pharma Inc.
Via GlobeNewswire
News headline image
First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
February 15, 2023
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
February 01, 2023
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
January 25, 2023
Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental 
Via PressReach
News headline image
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
January 25, 2023
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder
January 25, 2023
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25
January 24, 2023
From Small Pharma Inc.
Via GlobeNewswire
News headline image
First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026
January 09, 2023
Study will compare the profile of intramuscular versus intravenous SPL026 administration 
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property
December 22, 2022
From Small Pharma Inc.
Via GlobeNewswire
News headline image
First Patient Dosed in Small Pharma’s Drug Interaction Study
December 15, 2022
Open-label study will assess the interaction between SSRI antidepressants and SPL026 
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma To Support University College London Research Project on Neuroplasticity
December 14, 2022
Small Pharma will provide SPL026 for the brain-imaging study, which seeks to explore how psychedelic-induced brain changes impact cognition, behaviour and well-being 
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium
December 08, 2022
From Small Pharma Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap